Get the latest Science News and Discoveries

Novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia - EurekAlert!

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app